Literature DB >> 12045495

Complete mapping of a novel HLA A*6801-restricted HIV-1 Tat epitope directly with a rapid modified enzyme-linked immunospot assay.

Annette Oxenius1, Bent K Jakobsen, Philippa J Easterbrook, Jonathan M Boulter, Tin Tun, Anele Waters, Juliet Agudelo, Martin Barnardo, Rodney E Phillips, David A Price.   

Abstract

We identified a novel HLA A*6801-restricted HIV-1 Tat-derived cytotoxic T lymphocyte (CTL) epitope using an adapted enzyme-linked immunospot assay that allows the rapid ex vivo identification of CTL epitopes together with their associated HLA Class I restriction elements. The optimal 11 amino acid residue Tat epitope efficiently stabilized the refolding of monomeric peptide-HLA A6801 complexes in vitro and fluorochrome-labelled, tetrameric peptide-HLA A6801 complexes stained CD8 T cells specific for this epitope directly ex vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045495     DOI: 10.1097/00002030-200206140-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  2 in total

1.  HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.

Authors:  Philippa C Matthews; Emily Adland; Jennifer Listgarten; Alasdair Leslie; Nompumelelo Mkhwanazi; Jonathan M Carlson; Mikkel Harndahl; Anette Stryhn; Rebecca P Payne; Anthony Ogwu; Kuan-Hsiang Gary Huang; John Frater; Paolo Paioni; Henrik Kloverpris; Pieter Jooste; Dominique Goedhals; Cloete van Vuuren; Dewald Steyn; Lynn Riddell; Fabian Chen; Graz Luzzi; Thambiah Balachandran; Thumbi Ndung'u; Søren Buus; Mary Carrington; Roger Shapiro; David Heckerman; Philip J R Goulder
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

2.  Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor.

Authors:  Emma Gostick; David K Cole; Sarah L Hutchinson; Linda Wooldridge; Sabrina Tafuro; Bruno Laugel; Anna Lissina; Annette Oxenius; Jonathan M Boulter; David A Price; Andrew K Sewell
Journal:  Eur J Immunol       Date:  2007-02       Impact factor: 5.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.